| Identification | Back Directory | [Name]
(3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide | [CAS]
192755-52-5 | [Synonyms]
VX-740
HMR 3480
Pralnacasan
(3S,11S)-N-[(2R,3S)-2-ethoxy-5-oxo-oxolan-3-yl]-3-(isoquinoline-1-carbonylamino)-2,6-dioxo-1,7-diazabicyclo[5.4.0]undecane-11-carboxamide
(1S,9S)-N-[(2R,3S)-2-Ethoxy-5-oxotetrahydro-3-furanyl]-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxooctahydro-6H-pyridazino[1,2-a][1,2]diazepine-1-carboxamide
6H-Pyridazino[1,2-a][1,2]diazepine-1-carboxamide, N-[(2R,3S)-2-ethoxytetrahydro-5-oxo-3-furanyl]octahydro-9-[(1-isoquinolinylcarbonyl)amino]-6,10-dioxo-, (1S,9S)- | [Molecular Formula]
C26H29N5O7 | [MOL File]
192755-52-5.mol | [Molecular Weight]
523.54 |
| Hazard Information | Back Directory | [Uses]
Treatment of rheumatoid arthritis;
(interleukin-1β converting enzyme (also known as caspase-
1) inhibitor). | [Brand name]
Aventis; Vertex. | [in vivo]
Pralnacasan (0 -50 mg/kg; oral gavage; twice a day; for 6 weeks; female Balb/c mice) treatment reduces joint damage. Pralnacasan treatment does not appear to affect the weight of the animals[1]. | Animal Model: | Female Balb/c mice induced with collagenase[1] | | Dosage: | 0 mg/kg, 12.5 mg/kg, 25 mg/kg and 50 mg/kg | | Administration: | Oral gavage; twice a day; for 6 weeks | | Result: | Significantly ameliorated the histopathological damage of the medial knee joint compartments.
|
| [IC 50]
Interleukin-1β converting enzyme: 1.4 nM (Ki) | [storage]
Store at -20°C |
|
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|